From: Aberrant p16 methylation as an early diagnostic marker in blood of hepatocellular carcinoma patients
Parameter | P16 gene non-methylated patients (No. = 4) | P16 gene methylated patients (No. = 26) | H/F* | p value | |
---|---|---|---|---|---|
AST (IU/L) | Median (IQR), range | 46 (32.5–53.5), 20–60 | 68 (49–94), 23–242 | 21.5 | < 0.01* |
ALT (IU/L) | Median (IQR), range | 42.5 (32.5–67.5), 25–90 | 40 (26–76), 10–135 | 30.4 | < 0.01* |
Total bilirubin (mg/dL) | Median (IQR), range | 2.1 (1.15–8.8), 0.6–15.1 | 2 (1.3–3.4), 0.3–6.2 | 28.5 | < 0.01* |
Direct bilirubin (mg/dL) | Median (IQR), range | 0.7 (0.5–4.95), 0.4–9.1 | 0.75 (0.5–1.3), 0.1–2.8 | 40.5 | < 0.01* |
Albumin (g/dL) | Mean ± SD, range | 3.18 ± 0.76, 2.5–4.1 | 2.69 ± 0.65 1.5–3.7 | 64.6* | < 0.01* |
INR | Mean ± SD, range | 1.17 ± 0.18, 1.03–1.43 | 1.37 ± 0.24, 1–1.9 | 33.2* | < 0.01* |
AFP (ng/mL) | Mean ± SD, range | 5 (2.7–17.25), 1.9–28 | 131 (14–400), 2.3–3500 | 28.0 | < 0.01* |